Kornimate/medical-research-clean huggingface dataset:
international hernia mesh registry

Conditions: Hernia

Summary: this is an open-label, multi-center, long-term, prospective hernia mesh registry. a minimum of 4,800 hernia patients will be enrolled from approximately 60 active sites globally

patients will be followed for 2-years post-implantation, in a post-market setting to help identify best practices leading to lower recurrence rates and decreases in chronic pain, associated with the hernia repair procedure.

Eligibility criteria:
inclusion criteria patients must satisfy the following criteria before entering the registry: 1. provide written informed consent prior to surgery; 2. male or female patients that are \> 18 years of age; 3. be literate and able to understand a language available in the registry patient questionnaires; 4. scheduled to receive a surgically implanted ethicon synthetic mesh using any fixation method or a non-ethicon synthetic mesh which must be fixated with securestrap® or securestrap® open for repair of a hernia defect; 5. agree to provide long-term, outcomes data to quintiles outcome; 6. agree to provide contact information; 7. two or more pieces of the same mesh product sewn together will be considered as one mesh, and is therefore allowed in this registry exclusion criteria patients who meet any of the following criteria will be excluded from participating in the registry: 1. patients that are \<18 years of age; 2. patients who have been entered into the registry previously; 3. employees of the investigator or registry center with direct involvement in the proposed registry or other studies under the direction of that investigator or registry center and employees of ethicon; 4. patients suffering from and currently receiving medication for chronic pain (defined as suffering pain for greater than 3 months); 5. patients known to be suffering from pre-existing chronic depression; 6. patients currently known or suspected to abuse drugs or alcohol; 7. patients suffering from a terminal illness (e.g. cancer); 8. patients requiring multiple hernia repairs (including bilateral inguinal/femoral); 9. patients requiring any other (concomitant) surgical procedure; 10. patients suffering from an ongoing infection, sepsis, contaminated mesh or fistulas; 11. patients who require hiatal, paraesophageal or diaphragmatic hernia repair; 12. patients requiring two different types of meshes; 13. patients requiring two or more meshes not sewn together 14. patients scheduled to receive a surgically implanted biologic mesh product for repair of a hernia defect

Keywords: herniorrhaphy
can we predict chronic homelessness?

Conditions: Cognitive Impairment

Summary: homeless men and women suffer more illness and sooner death compared to housed people. among the homeless, there is a group that suffers more illness than others. this group is usually homeless for several months, makes up a smaller proportion of homeless people and uses more resources from emergency shelters than other homeless people. some have asked if a difference in thinking skills explains how people who are homeless for a long time need more help in getting and keeping housing compared to other homeless persons. in this study, thinking skills that help a person plan and make decisions will be screened among those who have been homeless for a long time and those who were homeless for a short time. if there is a difference, then screening may change how future homeless people get the help they need.


Eligibility criteria:
inclusion criteria: * men and women, greater than or equal to 18 years old, english speaking * group a: currently homeless and/or housed in an emergency shelter or housing facility for chronically homeless individuals ≥ 6 months * group b: not homeless ≥4 times in the last 3 years and currently living in stable housing ≥ 6 months and in the last 3 years, has been homeless ≤ 1 month exclusion criteria: at the time of testing, individuals with the following characteristics will be excluded: 1. altered mental status (determined by nurse coordinator through participant response to questions regarding orientation to person, place and season - score of at least 2/3 is considered intact mental status). 2. present intoxication (determined by nurse coordinator through participant evaluation of odour, either alcohol or non-beverage alcohol). 3. currently violent or aggressive towards testers (determined by nurse coordinator)

Keywords: homelessness
evaluation of cryoprotection induced nail toxicity docetaxel low cumulative dose

Conditions: Breast Neoplasms

Summary: for the specific patient population studied receiving 5-fluorouracil, epirubicin and cyclophosphamide - docetaxel sequence (cumulative dose \<300 mg / m2), using a cryoprotection has never been assessed. the effectiveness of cryoprotection of onycholysis secondary to docetaxel is not well established in this population (breast cancer in the adjuvant setting) and is based solely on a publication (scotté) that does not contain the same therapeutic modalities (dose significantly higher). the few studies available have heterogeneous populations, nonrandomized, retrospective or with a small sample. by extension to what has been observed with higher cumulative doses of docetaxel, some teams offer mittens and booties chilled to their patients, a practice that is not the subject of a national consensus. the investigators wish to accurately assess the effectiveness of mittens and slippers chilled, their tolerance and their observance because of weak data on this specific population in the literature.


Eligibility criteria:
inclusion criteria: * upper age to 18 years * mammary adenocarcinoma nonmetastatic and histologically proven * wait under an adjuvant or neoadjuvant chemotherapy according to the following conventional scheme: 3 cycles of f5-fluorouracil, epirubicin and cyclophosphamide 100 (500 or 5-fluorouracil 600 mg / m² j1, epirubicin 100 mg / m² j1, cyclophosphamide 500 or 600 mg / m² j1 or 3 cycles of epiribucin and cyclophosphamide 100) followed by 3 cycles of docetaxel, 100 mg / m², +/- trastuzumab if her2+++ * patient with the capacity/faculties to understand a newsletter and sign an informed consent * patient receiving social coverage * patient who can be treated and followed in the center for a period of at least one year * who scale 0 or 1 exclusion criteria: * age below 18 years * diseases of the scalp or whatever hair-showing against helmet or alopecia * using pre nail resin before and per chemotherapy * mammary adenocarcinoma stage iv * indication of docetaxel for cancer of another organ than breast * treatment processing or programmed during chemotherapy with an innovative molecule being evaluated * raynaud's syndrome, cold agglutinin disease, cryoglobulinemia and cryofibrinogenemia. * uncontrolled severe arterial disease. * presence of a device\> grade 1 neuropathy before the start of chemotherapy * patient unable to submit the protocol followed for psychological, social, family or geographical * patient with an incompatible underlying disease or concomitant with the inclusion in the trial, whether psychiatric or somatic * patient trust, guardianship, under legal protection measure, deprived of freedom * male * criteria for non randomization (before the first course of docetaxel) : * presence of peripheral neuropathy\> grade 1 after the first 3 cycles of 5-fluorouracil, epirubicin and cyclophosphamide 100. * presence of a nail or skin toxicity\> grade 1 after 3 cycles of 5-fluorouracil, epirubicin and cyclophosphamide 100.
dose ranging study to assess efficacy, safety and tolerability of pf-06700841 topical cream in psoriasis

Conditions: Psoriasis

Summary: this is a phase 2b, randomized, double blind, vehicle controlled, parallel group, multicenter study in participants with mild to moderate plaque psoriasis. the duration of study participation will be approximately 22 weeks, including up to a 6 week screening period, 12 week treatment period, and approximately 4 week follow up period. approximately 280 participants are planned to be randomized into the study.


Eligibility criteria:
inclusion criteria: * plaque psoriasis for 6 months * pga score mild or moderate * body surface area (bsa) 2-15% exclusion criteria: * other skin conditions that would interfere with the evaluation of psoriasis * history of herpes zoster or simplex * infected with mycobacterium tuberculosis

Keywords: psoriasis topical
diagnostic approach for cholangiocarcinoma using liquid bile biopsy

Conditions: Cholangiocarcinoma

Summary: the main aim of the study is to develop a diagnostic proteomic profile of cholangiocarcinoma using bile samples. the primary endpoint will be the rate of concordant positive diagnoses obtained from bile samples based on proteomic profiling compared with histological reference diagnoses (concomitant cytological sampling and/or final histological sampling).

cholangiocarcinoma has a poor 5-year prognosis (less than 5%) and is rarely resectable at diagnosis. diagnosis is made by histological sampling (biopsy or endo-biliary brushing) during endoscopic retrograde catheterization of the papilla or radiologically during transparietohepatic drainage. conventional histology techniques have a low sensitivity of around 14-60%, which leads to diagnostic delays, repeated invasive examinations and delays in therapeutic management, sometimes with progression from a resectable to an unresectable stage. new techniques are emerging to optimize the diagnosis of cholangiocarcinoma, in particular molecular techniques. this is the case with proteomics and proteomic profiling, which consists of obtaining diagnostic information from all the proteins contained in biological samples. furthermore, during diagnostic procedures for cholangiocarcinoma, bile samples are taken, initially for bacteriological purposes. proteomics has been shown to be a tool capable of identifying potential diagnostic biomarkers in bile samples. to date, proteomic profiling has never been tested on bile samples for diagnostic purposes, although its proof of concept has been established. obtaining a proteomic profile for the diagnosis of cholangiocarcinoma from bile samples would enable the development of an innovative tool that has not yet been described in this field. it would optimize the management of patients with cholangiocarcinoma, with the possibility of a quicker diagnosis enabling optimal management as soon as the first clinical symptoms appear, while reducing the number of examinations required to obtain a diagnosis.

Eligibility criteria:
inclusion criteria: * patient 18 years and older * patients with bile duct stenosis who require endoscopy with retrograde papillary catheterization or a radiological procedure for diagnostic purposes (histological samples) as part of their management * oral consent exclusion criteria: * pregnant woman * patient under legal protection

Keywords: cholangiocarcinoma diagnosis cancer proteomic profiling
covid-19 epidemic on acute stroke management

Conditions: Stroke, Acute

Summary: the covid-19 pandemic is a pandemic of an emerging infectious disease, coronavirus 2019 (covid-19), caused by the coronavirus sars-cov-2. it appears in november 2019 in the city of wuhan, china, and spreads worldwide from february 2020. the first cases of infection in france were confirmed on 24 january 2020. as of april 14, 103,573 cases of infection were confirmed, 32,292 hospitalized cases, including 6,730 in intensive care, with 15,729 deaths recorded1. the most affected regions are ile de france and the grand est (in particular the haut-rhin department). containment of the entire french population was introduced on 17 march, with the aim of reducing the spread of the virus and relieving the burden on the health system, particularly the intensive care units. this unprecedented health crisis, as well as the social containment measures in themselves, has repercussions on other acute medical pthologies, not directly related to the viral infection. it appears that the number of patients treated for acute stroke has suddenly declined since the beginning of the epidemic. however, it is not clear whether it is the incidence of stroke that has declined or simply the proportion of patients presenting within the time frame that allows for treatment in the acute phase (by thrombolysis or thrombectomy).


Eligibility criteria:
inclusion criteria: * adult patient * stroke patients * patient who agreed to participate in this study exclusion criteria: - refusal to participate in this study

Keywords: stroke , acute covid-19 sars-cov-2 mechanical thrombectomy thrombolysis
effects of imt on pulmonary functions in cases with inhalation injury

Conditions: Inhalation Injury; Pulmonary Function; Respiratory Muscle Strength

Summary: the current study aimed to investigate the effect of inspiratory muscle training (imt) on pulmonary functions (fev1and fvc), and respiratory muscle strength in patients with inhalation injury, which may prove to be a promising intervention helping to improve exercise tolerance, relieve dyspnea and suggests an improvement in respiratory muscle function.

forty male patients suffering from inhalation injury were been included in this study, participants' ages ranged from 20-35 years old. patients were selected from the burn department, om el-masreen hospital, and randomly assigned into two equal groups. the exercise group received inspiratory muscle training in addition to routine chest physiotherapy in the form of (deep breathing, coughing, and early ambulation) three times per week for four weeks (group a). the control group received only routine chest physiotherapy (group b). this study obtained ethical approval by the institutional review board of the faculty of physical therapy - cairo university, with reference number: p.t.rec/012/003431

Eligibility criteria:
inclusion criteria: * male patients suffering from inhalation injury. * participant age ranged from 20-35 years old. * all patients had the same medical care. * participants have received a good explanation of the treatment and measurement device. * treatment was conducted one month after inhalation injury. exclusion criteria: patients were excluded from this study for any of the following cases such as * instability of patient's medical condition. * presence of any diseases that could affect the study results. * participants having respiratory, cardiac, or neurological diseases that affect pulmonary functions.

Keywords: inspiratort training -inhalation injury
soothing and barrier restoration activity of a body cream for atopic skin

Conditions: Atopic Dermatitis

Summary: open clinical study to evaluate the soothing activity of a body cream to be applied once a day, mono-laterally at level of the antecubital fold and forearm, for an uninterrupted period of 1 month, by 22 adult volunteers, with positive anamnesis for atopy and habitual itching.


Eligibility criteria:
inclusion criteria: * adult volunteers of both sexes * volunteers with positive anamnesis for atopy and habitual itching * volunteers in a good general state of health in the investigator opinion * negative pregnancy test (only for female subjects not in menopause) * accepting to follow the instructions received by the investigator * accepting to not change their habits regarding food, physical activity, body cleansing * agreeing not to apply or take any product/drug or use body massages able to change skin conditions during the entire duration of the study * accepting not to expose their face to strong uv irradiation (uv session, or sun bathes), during the entire duration of the study * no participation in a similar study currently or during the previous 3 months * volunteers who are giving a written informed consent. exclusion criteria: * pregnancy (only for female subjects not in menopause) * lactation (only for female subjects not in menopause) * change in the normal habits in the last month * participation in a similar study during the previous 3 months * known allergy to one or several ingredients of the product on trial * insufficient adhesion to the study protocol * dermatitis * presence of cutaneous disease on the tested area, as lesions, scars, malformations * clinical and significant skin condition on the test area. * diabetes * endocrine disease * hepatic disorder * renal disorder * cardiac disorder * pulmonary disease * cancer * neurological or psychological disease * inflammatory/immunosuppressive disease * drug allergy. * anti-histaminic, topic and systemic corticosteroids, narcotic, antidepressant, immunosuppressive drugs (with the except of contraceptive or hormonal treatment starting more than 1 year ago) * using of drugs able to influence the test results in the investigator opinion.
evaluation of the retina of subjects without diabetes mellitus and subjects with diabetes mellitus without diabetic retinopathy using optical coherence tomography

Conditions: Diabetic Retinopathy

Summary: the purpose of this study is to evaluate topographic features of the posterior pole of the eye in normal subjects as well as in subjects with diabetes mellitus but without diabetic retinopathy (dr) using optical coherence tomography (oct). the investigators proposal is a novel study to determine retinal volume of normal and diabetic subjects without dr. specifically, the investigators will establish a standardized reference range for retinal thickness and volume that will provide standards for oct analysis of different clinical trials for retinal diseases.


Eligibility criteria:
inclusion criteria: * healthy retinas * willingness to sign informed consent to have oct images taken. exclusion criteria: * no macular pathology * no diabetes
cilostazol-ginkgo for cognitive function in elderly diabetes

Conditions: Type 2 Diabets Mellitus; Cognitive Ability, General

Summary: this exploratory pilot study aims to evaluate the cognitive improvement effects of combination therapy with cilostazol (200 mg) and ginkgo biloba extract (160 mg) in elderly patients with type 2 diabetes mellitus. both agents have demonstrated potential cognitive benefits through mechanisms such as enhanced cerebral blood flow, anti-inflammatory activity, and neuroprotection. given the increased risk of cognitive decline and dementia in patients with type 2 diabetes, and the need for preventive strategies, this study will investigate whether the combination therapy can prevent or mitigate cognitive deterioration. findings from this study may provide foundational data for the future development of therapeutic interventions targeting cognitive impairment in patients with diabetes.


Eligibility criteria:
inclusion criteria: * patients diagnosed with type 2 diabetes mellitus * adults aged 60 years or older * patients with a mini-mental state examination (mmse) score between 24 and 28 within the past 3 months exclusion criteria: * patients with type 1 diabetes mellitus, diabetic ketoacidosis, or diabetic coma or precoma * patients with poorly controlled blood glucose (hba1c \> 10.0%) * patients with an mmse score below 24 * patients diagnosed with dementia (e.g., alzheimer's disease) * patients with suspected cognitive impairment due to other causes * patients requiring antiplatelet or anticoagulant therapy other than the investigational product * patients with thyroid dysfunction requiring treatment (i.e., abnormal tsh levels) * patients with severe depression * patients with severe infections, recent surgery (perioperative status), or major trauma * patients with pituitary or adrenal insufficiency * patients with other medical conditions requiring hospitalization * patients with a history of alcohol or drug abuse within 1 year prior to screening * patients with a history of taking medications that may affect cognitive function within 3 months prior to screening * patients deemed by the investigator to be otherwise unsuitable for study participation
eliminate risk of cardiac surgical site events

Conditions: Surgical Site Infections

Summary: the purpose of the study is to see if using 2% chlorhexidine cloths will reduce surgical site infections in patients having elective cardiac surgery.

a randomized, prospective study utilizing 2% chlorhexidine cloths to evaluate the product's effectiveness in reducing surgical site infections in elective cardiothoracic surgery patients. sage 2% chlorhexidine cloths are approved by the food and drug administration (fda) for preparation of skin prior to surgery. the study hypothesis is that the preoperative surgical preparation with 2% chlorhexidine cloths, which leaves chlorhexidine on the skin, will reduce surgical site infections by 50% as compared to current standard procedure.

Eligibility criteria:
inclusion criteria: * elective cardiothoracic surgery patients \> 18 years old. * informed consent obtained exclusion criteria: * any current known allergies to chlorhexidine gluconate * currently taking any oral or topical antibiotics * any active skin rashes or breaks in the skin on areas to be treated with chlorhexidine gluconate * a current active skin disease or inflammatory skin condition, known pre-existing skin infection, including contact dermatitis that is currently being treated with an antibiotic * any medical condition or use of any medications that in the opinion of the principal investigator preclude participation. * unwillingness or failure to fulfill requirements of the study

Keywords: adult cardiac surgery surgery site infections